Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Salmonella And E. Coli Bacteria Found In Packets Of Shelled Nuts
A recent study carried out by the Health Protection Agency and LACORS (Local Authorities Co-ordinators of Regulatory Services) has revealed the presence of Salmonella and E. coli bacteria in a small number of samples of ready-to-eat shelled nuts.
generic viagra online
Family Doctors: An Endangered Breed
"As more medical students shun primary care for higher-paid specialties, experts warn of a severe imbalance that could cripple the nation"s health care system," CNN Money reports. Luis Manriquez, a first-year student at the University of Washington School of Medicine wants to become a family doctor, an increasingly rare ambition. He will "probably make one-fourth the salary of a specialist while trying to pay down $140,000 on average in medical school debt." Manriquez says that "primary care physicians are considered to not do as much as specialists. ò€¦ People have told me that generalists are less respected as doctors."
News of the day
Brain Activity Stablilized By Dynamic Molecular Mechanism
In the brain, many types of synaptic proteins are spatio-temporally regulated to maintain synaptic activity at a constant level. Here, the Japanese research group led by Professor Masaki Fukata, Drs. Yuko Fukata and Jun Noritake in National Institute for Physiological Sciences, Japan, found that two types of palmitoylating enzymes finely-tune the location and function of a major synaptic protein, PSD-95, in different ways. They also found that this mechanism contributes to keeping synaptic activity stable when synaptic activity dynamically changes. The Japan Science and Technology Agency (JST) supported this study. They report the finding in Journal of Cell Biology published on July 13, 2009.
Endocrinology

DxS' TheraScreen(R) K-RAS Companion Diagnostic Approved For Use With Amgen's Vectibix™ In Canada

DxS, a personalised medicine company, has had its TheraScreen: K-RAS Mutation Kit granted a licence by the regulatory body Health Canada for use as a diagnostic for anti-EGFR therapies and as the companion diagnostic for Amgen"s colorectal cancer therapy, Vectibix™ (panitumumab). The availability of the TheraScreen: K-RAS Mutation Kit will allow colorectal cancer patients in Canada to be screened using the DxS diagnostic to assess their suitability for treatment with Vectibix™. Studies have shown that patients with the non-mutated K-RAS gene may respond to treatment with Vectibix™. Approximately 60 per cent of metastatic colorectal cancer patients have a non-mutated K-RAS gene. Colorectal cancer is the third-leading cause of cancer death in Canada, with around 22,000 diagnosed each year, causing 9,100 deaths1. Dr. Kenneth Pritzker, Mount Sinai Services, Toronto, one of the leading centres carrying out K-RAS testing in Canada said "This is extremely good news that we now have a registered method for K-RAS testing. The DxS K-RAS test is simple to use, highly sensitive and is the companion diagnostic test of choice for assessing a patient"s response to Vectibix™." The approval of the TheraScreen: K-RAS Mutation Kit is a step forward in making personalised medicine more readily available to physicians and patients in Canada. The future of cancer treatment will be guided by the use of technological advances such as these, which enable physicians to better manage a patient"s disease or predisposition towards a disease. Now physicians can choose a treatment approach that is likely to work best in the context of a patient"s genetic and environmental profile. Following the global distribution agreement signed in 2008, Roche Diagnostics will be distributing and supporting sales of the TheraScreen: K-RAS Mutation Kit in Canada beginning in August of this year. About colorectal cancer This year an estimated 22,000 Canadians will be diagnosed with colorectal cancer and 9,100 will die from it. On average, 413 Canadians will be diagnosed with colorectal cancer every week and 171 will die from the disease weekly. One in 14 men is expected to develop colorectal cancer during his lifetime and one in 27 will die from it. One in 16 women is expected to develop colorectal cancer during her lifetime and one in 31 will die from it. Overall, colorectal cancer is the third-leading cause of cancer death in Canada. 1 Data from the Colorectal Association of Canada, http://www.colorectal-cancer.ca DxS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009